TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2136970

Group type: EXPERIMENTAL
Intervention: TPN with long-chain triglycerides (LCTs)
Number of subjects: 75

Group type: COMPARATOR
Intervention: TPN with medium-chain triglycerides (MCTs) and long-chain triglycerides (LCTs)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: TPN with glucose-fat-based TPN (LCTs)
Number of subjects: 75

Group type: COMPARATOR
Intervention: TPN with glucose-fat-based TPN (MCTs and LCTs)
Number of subjects: 75
Study: 74730

Group type: EXPERIMENTAL
Intervention: 150 mg oestradiol in viscous gel
Number of subjects: 25

Group type: COMPARATOR
Intervention: Viscous gel alone
Number of subjects: 25
Study: 31355775

Group type: EXPERIMENTAL
Intervention: Doravirine 100 mg
Number of subjects: 216

Group type: COMPARATOR
Intervention: Efavirenz 600 mg
Number of subjects: 216
Study: 28537062

Group type: EXPERIMENTAL
Intervention: MVA.HIVconsv (5.5 × 10^7 pfu, n=8)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: MVA.HIVconsv (2.2 × 10^8 pfu, n=7)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo (n=4)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 19
Study: 25964839

Group type: EXPERIMENTAL
Intervention: Shockwave lithotripsy (SWL)
Number of subjects: 206
Study: 23553449

Group type: EXPERIMENTAL
Intervention: Study group (palpated pilot balloons of tracheostomy tube cuffs inflated to three different pressures)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control group (viewed a video about inflating tracheostomy tube cuffs)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Study group
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 49
Study: 21807891

Group type: EXPERIMENTAL
Intervention: tacrolimus/MMF
Number of subjects: 150

Group type: COMPARATOR
Intervention: tacrolimus/sirolimus
Number of subjects: 150

Group type: COMPARATOR
Intervention: cyclosporine/sirolimus
Number of subjects: 150

Group type: COMPARATOR
Intervention: sirolimus
Number of subjects: 150
Study: 18842612

Group type: EXPERIMENTAL
Intervention: Weekly paclitaxel (Pw)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Paclitaxel with carboplatin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Gemcitabine with docetaxel (GDoc)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Weekly paclitaxel (Pw) vs GDoc
Number of subjects: 0
Study: 16478772

Group type: EXPERIMENTAL
Intervention: High liver fat content (17.4 +/‐ 8.0%)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Low liver fat content (4.6 +/‐ 2.0%)
Number of subjects: 55
Study: 15243470

Group type: EXPERIMENTAL
Intervention: Pilocarpine (5 mg, PILO, n=29)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo (PLA, n=29)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Pilocarpine (5 mg, PILO)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 58
Study: 11679972

Group type: EXPERIMENTAL
Intervention: High-dose interferon induction therapy (Group A: 10 MU IntronA/day for 2 weeks, then 10 MU/2 days for 12 weeks)
Number of subjects: 373

Group type: EXPERIMENTAL
Intervention: Low-dose interferon therapy (Group B: 5 MU/day for 14 weeks)
Number of subjects: 373

Group type: EXPERIMENTAL
Intervention: Low-dose interferon therapy (Group C: 5 MU/2 days for 14 weeks)
Number of subjects: 373

Group type: EXPERIMENTAL
Intervention: High-dose interferon induction therapy (Group A) in genotype 1 patients
Number of subjects: 373

Group type: EXPERIMENTAL
Intervention: Low-dose interferon therapy (Group B) in genotype 1 patients
Number of subjects: 373

Group type: EXPERIMENTAL
Intervention: Low-dose interferon therapy (Group C) in genotype 1 patients
Number of subjects: 373

Group type: EXPERIMENTAL
Intervention: High-dose interferon induction therapy (Group A) in genotype 3a patients
Number of subjects: 373

Group type: EXPERIMENTAL
Intervention: Low-dose interferon therapy (Group B) in genotype 3a patients
Number of subjects: 373

Group type: EXPERIMENTAL
Intervention: Low-dose interferon therapy (Group C) in genotype 3a patients
Number of subjects: 373
Study: 9597561

Group type: EXPERIMENTAL
Intervention: OROS formulation (75 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: IR formulation (75 mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 24
Study: 8169026

Group type: EXPERIMENTAL
Intervention: Capsaicin cream applied for 3 weeks
Number of subjects: 68

Group type: COMPARATOR
Intervention: Untreated control arm
Number of subjects: 68
Study: 3166930

Group type: EXPERIMENTAL
Intervention: Nebuhaler technique with five breaths sufficient to operate the Nebuhaler valve
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Nebuhaler technique with two deep inspirations from residual volume held for 5 seconds
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 31916633

Group type: EXPERIMENTAL
Intervention: Self-directed learning (self-evaluation)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Peer feedback (peer evaluation)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Expert feedback
Number of subjects: 110
Study: 31392991

Group type: EXPERIMENTAL
Intervention: Functional Strength Integration (FSI) intervention
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (CON) with standard of care exercise program
Number of subjects: 100
Study: 28861513

Group type: EXPERIMENTAL
Intervention: Contingency management (CM) for alcohol
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Cannabis users
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Cannabis use
Number of subjects: 121
Study: 25287214

Group type: EXPERIMENTAL
Intervention: Ponesimod 40 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ponesimod 100 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 23597235

Group type: EXPERIMENTAL
Intervention: Gardening intervention including a fruit and vegetable garden, monthly curriculum, gardening support, and technical assistance
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control centers (no gardening intervention)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Gardening intervention
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control centers
Number of subjects: 6
Study: 21658030

Group type: EXPERIMENTAL
Intervention: Utilitarian priming
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hedonic priming
Number of subjects: 0
Study: 18359420

Group type: EXPERIMENTAL
Intervention: Clinician judgment of VAP probability at the time of CSVAP
Number of subjects: 740

Group type: EXPERIMENTAL
Intervention: Retrospective adjudication of VAP
Number of subjects: 740

Group type: EXPERIMENTAL
Intervention: CSVAP occurrence >7 days after start of mechanical ventilation
Number of subjects: 740

Group type: EXPERIMENTAL
Intervention: Negative index cultures
Number of subjects: 740

Group type: EXPERIMENTAL
Intervention: Bacteremia
Number of subjects: 740
Study: 16522412

Group type: EXPERIMENTAL
Intervention: Valacyclovir 500 mg twice daily until delivery
Number of subjects: 112

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study: 12771610

Group type: EXPERIMENTAL
Intervention: Subcutaneous enoxaparin 40 mg daily
Number of subjects: 29
Study: 10695617

Group type: COMPARATOR
Intervention: LAC (lansoprazole 30 mg twice a day, amoxicillin 500 mg three times a day, clarithromycin 200 mg twice a day)
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: RAC (rabeprazole 20 mg twice a day, amoxicillin 500 mg three times a day, clarithromycin 200 mg twice a day)
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: R1/2AC (rabeprazole 10 mg twice a day, amoxicillin 500 mg three times a day, clarithromycin 200 mg twice a day)
Number of subjects: 308
Study: 9352986

Group type: EXPERIMENTAL
Intervention: Norvasc (Amlodipine)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Carotid ultrasound examinations
Number of subjects: 0
Study: 1347801

Group type: EXPERIMENTAL
Intervention: Aspirin plus heparin
Number of subjects: 41299

Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 41299

Group type: EXPERIMENTAL
Intervention: Streptokinase (SK)
Number of subjects: 41299

Group type: COMPARATOR
Intervention: Anistreplase (APSAC)
Number of subjects: 41299
Study: 3915886

Group type: EXPERIMENTAL
Intervention: Tenoxicam 20 mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Piroxicam 20 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Tenoxicam (continued treatment)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Piroxicam (switched to tenoxicam)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Tenoxicam and Piroxicam
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Tenoxicam
Number of subjects: 30
Study: 31022704

Group type: EXPERIMENTAL
Intervention: Probiotic group (Streptococcus salivarius M18)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 64
Study: 30265040

Group type: EXPERIMENTAL
Intervention: Concurrent Treatment of PTSD and SUD Using Prolonged Exposure (COPE)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Relapse Prevention Therapy (RPT)
Number of subjects: 0
Study: 25972081

Group type: EXPERIMENTAL
Intervention: PRF/DFDBA
Number of subjects: 30

Group type: COMPARATOR
Intervention: DFDBA/saline
Number of subjects: 30
Study: 25024230

Group type: EXPERIMENTAL
Intervention: Strabismus
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anisometropia
Number of subjects: 0
Study: 22686162

Group type: EXPERIMENTAL
Intervention: Operand format switched across trials (digits or words) with operator alternating between blocks.
Number of subjects: 84

Group type: COMPARATOR
Intervention: Operator switched across trials, operand format alternated between blocks.
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Digit operands with + when format switched.
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Word problems with operand format blocked.
Number of subjects: 84
Study: 20435232

Group type: EXPERIMENTAL
Intervention: Desirudin (15 mg SC q12h for patients without thrombosis; 30 mg SC q12h for patients with thrombosis)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Argatroban (administered by continuous intravenous infusion according to approved prescribing information or institutional guidelines)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Desirudin
Number of subjects: 16

Group type: COMPARATOR
Intervention: Argatroban
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Desirudin and Argatroban
Number of subjects: 16
Study: 18922983

Group type: EXPERIMENTAL
Intervention: Physical activity monitoring (sedentary vs. less sedentary)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Antihypertensive drugs
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Monitoring during 12 a.m. to 8 a.m.
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Sleep activity levels in nondippers vs. dippers
Number of subjects: 24
Study: 15852624

Group type: EXPERIMENTAL
Intervention: Dexamethasone 8 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 20
Study: 12452228

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (15 mg/kg intravenously before skin incision and a second bolus of 15 mg/kg at the end of CPB)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Saline placebo (administered at the end of CPB)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 67

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 67
Study: 11192338

Group type: EXPERIMENTAL
Intervention: Sleep hygiene plus bed restriction (restricting time in bed by 30 minutes nightly for one year)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Sleep hygiene alone
Number of subjects: 21
Study: 9391292

Group type: EXPERIMENTAL
Intervention: Ibopamine 100 mg three times daily
Number of subjects: 266

Group type: COMPARATOR
Intervention: Captopril 25 mg three times daily
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 266
Study: 8134321

Group type: EXPERIMENTAL
Intervention: Educational plus behavioral strategies (goal-setting, self-monitoring, positive reinforcement, telephone follow-up at 2, 4, 6 and 12 weeks)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Educational strategies alone (providing verbal and written information, tailoring to individuals' needs, collaborating with patients)
Number of subjects: 54
Study: 3440095

Group type: EXPERIMENTAL
Intervention: Morning dosing of theophylline
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Evening dosing of theophylline
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Both morning and evening dosing of theophylline
Number of subjects: 13
Study: 30040765

Group type: EXPERIMENTAL
Intervention: Vestibular rehabilitation (VR) training for 4 weeks
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Between-group comparison
Number of subjects: 25
Study: 28045720

Group type: EXPERIMENTAL
Intervention: Presence of obesity and hypertension
Number of subjects: 379

Group type: EXPERIMENTAL
Intervention: Presence of diabetes, hypertension, obesity, and their combinations (dyads, triads, quads)
Number of subjects: 379
Study: 24880000

Group type: EXPERIMENTAL
Intervention: EMPOWER intervention (hospice staff education, screening of barriers, discussions with caregivers and patients)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: EMPOWER intervention
Number of subjects: 126
Study: 23277296

Group type: EXPERIMENTAL
Intervention: MEO approach
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: LEO approach
Number of subjects: 80
Study: 21622676

Group type: EXPERIMENTAL
Intervention: Contingent Paid Training group
Number of subjects: 124

Group type: COMPARATOR
Intervention: Paid Training group
Number of subjects: 124

Group type: COMPARATOR
Intervention: Unpaid Training group
Number of subjects: 124
Study: 18606622

Group type: EXPERIMENTAL
Intervention: 1.36% glucose instillation (A)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 3.86% glucose instillation (B)
Number of subjects: 22
Study: 16926313

Group type: EXPERIMENTAL
Intervention: Direct bonding technique
Number of subjects: 33

Group type: COMPARATOR
Intervention: Indirect bonding technique
Number of subjects: 33
Study: 12623326

Group type: EXPERIMENTAL
Intervention: Inhalation of tea catechin extracts (3.7 g/L catechins, 43% epigallocatechin gallate), three times daily for four weeks.
Number of subjects: 24

Group type: COMPARATOR
Intervention: Inhalation of saline/bromhexine alone (control group).
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Inhalation of tea catechin extracts.
Number of subjects: 24
Study: 10874805

Group type: EXPERIMENTAL
Intervention: Commercially pure titanium implants
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Coated implants
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Implant sites
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control sites
Number of subjects: 59
Study: 9169208

Group type: EXPERIMENTAL
Intervention: Presentation of compounds with conflicting reinforcement histories
Number of subjects: 0

Group type: COMPARATOR
Intervention: Presentation of compounds containing some or all novel components
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multiple testing procedures
Number of subjects: 0
Study: 8249176

Group type: EXPERIMENTAL
Intervention: IL-2 plus low-dose MPA (500 mg orally one day/week)
Number of subjects: 30

Group type: COMPARATOR
Intervention: IL-2 alone (3 million IU twice/day for 5 days/month subcutaneously)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: IL-2 plus low-dose MPA
Number of subjects: 30
Study: 29359677

Group type: EXPERIMENTAL
Intervention: Nutraceuticals for erectile dysfunction
Number of subjects: 74
Study: 28437237

Group type: EXPERIMENTAL
Intervention: Hypothermia as adjunctive therapy to PCI
Number of subjects: 119

Group type: COMPARATOR
Intervention: Standard care with PCI only
Number of subjects: 119
Study: 26256131

Group type: EXPERIMENTAL
Intervention: Punica granatum peel extract (6 g of dry peel/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 23299764

Group type: EXPERIMENTAL
Intervention: Terbutaline (8 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 21252645

Group type: EXPERIMENTAL
Intervention: Wrapped warm footbath (WW-footbath)
Number of subjects: 18
Study: 18616538

Group type: EXPERIMENTAL
Intervention: Intralesional bleomycin
Number of subjects: 0
Study: 16710647

Group type: COMPARATOR
Intervention: Pulsed infrared light therapy (PILT) administered to one foot, 24 treatments (3 times/week for 8 weeks, 30 min each).
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (no treatment) on the other foot.
Number of subjects: 22
Study: 14562491

Group type: EXPERIMENTAL
Intervention: Educational intervention (weekly psychoeducation classes focused on nutrition, exercise, and healthy lifestyle)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 70
Study: 10758470

Group type: EXPERIMENTAL
Intervention: Epidural diamorphine 2.5 mg followed by PCA bolus 1 mg with a 20‐min lockout (Gp1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Subcutaneous diamorphine 2.5 mg followed by PCA bolus with a 10‐min lockout period (Gp2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Epidural diamorphine 2.5 mg in 4 mL of 0.125% (w/v) bupivacaine followed by PCA bolus of 1 mg diamorphine in 4 mL 0.125% (w/v) bupivacaine with a 20‐min lockout (Gp3)
Number of subjects: 0
Study: 8642363

Group type: EXPERIMENTAL
Intervention: Bodily amplification and daily life stress interaction at inception
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Four-step model including bodily amplification, daily life stress, age, and education level
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Bodily amplification and daily irritants interaction at baseline
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Total number of ventricular premature contractions during monitoring
Number of subjects: 67
Study: 1329683

Group type: EXPERIMENTAL
Intervention: Handsewn ileoanal anastomosis (IAA) with a defunctioning loop ileostomy (Group I)
Number of subjects: 483

Group type: EXPERIMENTAL
Intervention: Stapled IAA with a defunctioning ileostomy (Group II)
Number of subjects: 483

Group type: EXPERIMENTAL
Intervention: Stapled IAA with no covering ileostomy (Group III)
Number of subjects: 483

Group type: EXPERIMENTAL
Intervention: Patients with healed IAA after a leak
Number of subjects: 483

Group type: COMPARATOR
Intervention: Patients with omitted ileostomy
Number of subjects: 483
Study: 4018501

Group type: EXPERIMENTAL
Intervention: Nifedipine 10 mg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Nifedipine 20 mg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Nifedipine 30 mg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Nifedipine (all doses)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 30585532

Group type: EXPERIMENTAL
Intervention: Mothering from the Inside Out (MIO)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Parent Education (PE)
Number of subjects: 15
Study: 29760027

Group type: EXPERIMENTAL
Intervention: V1SAGES case management intervention
Number of subjects: 247

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 247
Study: 27620899

Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Ziprasidone
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: FLI score ≥60
Number of subjects: 191
Study: 23973795

Group type: EXPERIMENTAL
Intervention: Early feeding starting on day 2 after birth
Number of subjects: 404

Group type: COMPARATOR
Intervention: Late feeding starting on day 6 after birth
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: Infants <29 weeks
Number of subjects: 404
Study: 22394666

Group type: EXPERIMENTAL
Intervention: Health mentoring by trained general practice nurses
Number of subjects: 19
Study: 20345272

Group type: EXPERIMENTAL
Intervention: Steroid-coated (triamcinolone acetonide 1%) 18F hydrophilic dilatation catheter for 2 weeks
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 18F hydrophilic dilatation catheter for 2 weeks
Number of subjects: 45

Group type: COMPARATOR
Intervention: 18F silicone urethral catheter for 3 days
Number of subjects: 45
Study: 17127776

Group type: EXPERIMENTAL
Intervention: Intranasal midazolam (0.2 mg/Kg)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Intravenous diazepam (0.3 mg/Kg)
Number of subjects: 125
Study: 15530132

Group type: COMPARATOR
Intervention: Single oral doses of L-T4 tablets (25, 50, 75, 100, 125, 150, 175, 200 microg per tablet; total doses 600, 625 or 700 microg)
Number of subjects: 169

Group type: COMPARATOR
Intervention: Liquid formulation of L-T4
Number of subjects: 169
Study: 11587406

Group type: EXPERIMENTAL
Intervention: Failed renal transplant patients (fTx)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Never-transplanted PD patients (non-Tx)
Number of subjects: 42
Study: 9303630

Group type: EXPERIMENTAL
Intervention: Hepatic intraarterial cisplatin + hyaluronidase
Number of subjects: 10

Group type: COMPARATOR
Intervention: Cisplatin alone
Number of subjects: 10
Study: 8281530

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 20
Study: 3471936

Group type: EXPERIMENTAL
Intervention: Oral methotrexate (n = 11)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Intramuscular methotrexate (n = 7)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Oral methotrexate (dosages ≤ 40 mg/m2)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Oral methotrexate (dosages > 40 mg/m2)
Number of subjects: 12
Study: 31978697

Group type: EXPERIMENTAL
Intervention: Intranasal steroids (INS)
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Antihistamine (ATH) combined with leukotriene receptor antagonists (LRA)
Number of subjects: 267

Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 267
Study: 31819385

Group type: EXPERIMENTAL
Intervention: Tai Chi exercise (weekly classes and home practice for 20 weeks)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 85
Study: 27736289

Group type: EXPERIMENTAL
Intervention: Foam Rolling
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Dynamic Stretching
Number of subjects: 30

Group type: COMPARATOR
Intervention: Static Stretching
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (Static Stretching)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (Dynamic Stretching)
Number of subjects: 30